Dr. O’Shaughnessy on Using Phosphoprotein Assays for Treatment Decision-Making for Breast Cancer

Joyce A. O’Shaughnessy, MD, of the Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses the use of phosphoprotein analysis in decision-making for triple negative breast cancer patients.  She highlights a subset of triple negative breast cancer patients  with elevated phospho-EGFR and activated downstream signaling pathways, as determined by proteomic analysis, who responded to anti-EGFR directed therapies.

View Dr. O’Shaughnessy’s video discussion at OncLive.                              OncLive_reduced

To learn more about phosphoprotein testing of breast cancer using the TheraLink® Assay for Breast Cancer or to order a test.